The Annals Evolution of Clinical Pharmacy | Now Available
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 16 January 2007, www.theannals.com, DOI 10.1345/aph.1H220.
 The Annals of Pharmacotherapy: Vol. 41, No. 2, pp. 309-313. DOI 10.1345/aph.1H220
© 2007 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Baun, R. F
Right arrow Articles by Levy, H. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Baun, R. F
Right arrow Articles by Levy, H. B.

DRUG INFORMATION ROUNDS

Tegaserod for Treating Chronic Constipation in Elderly Patients

Ronald F Baun, PharmD

at time of writing, PharmD Student, St. Louis College of Pharmacy, St. Louis, MO; now, Pharmacy Practice Resident, University of Missouri Hospital, Columbia, MO

Hedva Barenholtz Levy, PharmD BCPS CGP

Director, HbL PharmaConsulting; Lecturer, University of Missouri, St. Louis, MO; Adjunct Instructor of Pharmacy Practice, St. Louis College of Pharmacy

Reprints: Dr. Levy, 9648 Olive Blvd., Ste. 309, St. Louis, MO 63132-3002, fax 314/994-9409, hedva{at}hblpharm.com

OBJECTIVE: To evaluate data that address the safety and efficacy of tegaserod for the management of chronic constipation (CC) in elderly patients.

DATA SOURCES: Primary literature was identified through MEDLINE (1966-January 2007) and EMBASE (2002-January 2007) using the search terms tegaserod, elderly, and constipation. Additional information was requested from the pharmaceutical manufacturer.

STUDY SELECTION AND DATA EXTRACTION: Clinical trials evaluating the efficacy and safety of tegaserod for treating CC were considered for inclusion. Emphasis was placed on data relevant to use of tegaserod in the elderly and on CC.

DATA SYNTHESIS: Two efficacy trials evaluated tegaserod for treating constipation. They enrolled a total of 331 elderly patients, comprising approximately 13% of study patients. Tegaserod was effective for improving constipation in the overall study populations; no significant adverse events were noted. However, both studies lacked a subgroup analysis in the elderly. Diarrhea occurred more commonly with higher doses of tegaserod and may be a concern in older adults. A 13 month safety trial found tegaserod to be well tolerated for treatment of constipation, with similar adverse events seen as in the 12 week efficacy studies. Specific data were not provided for elderly patients.

CONCLUSIONS: Tegaserod should not replace current therapies for treatment of CC in the elderly. The drug has been studied in a small number of older adults; thus, data are inconclusive about its use in this population. Older adults have a higher risk of diarrhea with tegaserod. Cautious use is warranted until further studies specifically address the elderly population.

Key Words: constipation, elderly, tegaserod

Published Online, January 16, 2007. www.theannals.com, DOI 10.1345/aph.1H220




homecopy help contact us subscription past issues search current issue
Copyright © 2007 by Harvey Whitney Books Company.